Gilead says an analysis of clinical trial and retrospective real-world data suggest remdesivir can improve survival in severe COVID-19 infections, but adds controlled studies a
The first healthy volunteer has been dosed with Imperial College London’s coronavirus vaccine, the second UK-developed candidate to reach the clinical testing stage.
Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from newborns to adolescents – who have moderate-to-severe COVID-19.
Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to
US biotech BioSig Technologies’ subsidiary ViralClear has been cleared by the FDA to start a phase 2 trial of its antiviral drug merimepodib in patients who are severely ill wi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.